MANILA, Philippines — Ayala Corporation is positioning its healthcare business for a potentially major expansion after appointing a former top executive of Thailand’s internationally recognized Bumrungrad International Hospital to lead AC Health, amid reports that another foreign medical group could soon join its growing healthcare platform.
Dr. Num Tanthuwanit, former chief executive officer and medical director of Bumrungrad International Hospital in Bangkok, has taken over as president and CEO of Ayala Healthcare Holdings Inc. (AC Health), according to an October 12 report by InsiderPH.
His appointment comes as the Ayala Group seeks to expand its network of hospitals, specialty clinics and pharmaceutical businesses while exploring new opportunities in medical tourism.
But an even bigger development could be emerging behind the scenes.
InsiderPH reported that a large foreign medical group is being considered as a potential new partner for AC Health, raising the possibility of additional international expertise and a deeper expansion of the company’s hospital operations.
The prospective partner has not been publicly identified, and the structure, scope and timing of any transaction remain unconfirmed.
From Bangkok’s Bumrungrad to Ayala’s Healthcare Empire
Tanthuwanit brings significant experience in international hospital operations, healthcare management and strategic expansion.
Before joining AC Health, he led Bangkok’s Bumrungrad International Hospital, a major private medical institution recognized for serving both domestic and international patients.
He also previously headed Indonesia’s OMNI Hospitals Group and worked with EY-Parthenon’s healthcare strategy and transactions practice.
His background combines clinical experience, hospital operations and healthcare investments — capabilities that could prove valuable as Ayala pursues a more integrated healthcare business.
For AC Health, appointing an executive familiar with international hospital management could help strengthen clinical operations, improve patient services and support expansion into higher-value specialty treatments.
It could also accelerate the company’s ambitions in medical tourism, a segment in which hospitals compete to attract patients seeking treatment outside their home countries.
Ayala Eyes Medical Tourism as a New Growth Opportunity
One of the most significant aspects of Tanthuwanit’s appointment is his experience with Bumrungrad’s international patient business.
Medical tourism has become an important competitive area for private hospitals across Asia, with patients traveling abroad for specialist consultations, complex procedures, preventive care and other treatments.
Thailand and Singapore are established destinations for international medical patients, while the Philippines has opportunities to expand its own presence in the market.
For Ayala, medical tourism could represent a new revenue opportunity alongside its existing hospital, clinic and pharmaceutical businesses.
However, building a successful international patient business requires more than modern hospitals.
Medical institutions must demonstrate strong clinical outcomes, internationally competitive specialist services, dependable patient coordination, transparent pricing and recognized quality standards.
AC Health would also need to strengthen its ability to serve overseas patients while continuing to address the healthcare needs of Filipinos.
Tanthuwanit’s appointment could provide relevant operational expertise, but any expansion into medical tourism will depend on investment, execution and patient demand.
A Mystery Foreign Healthcare Partner Could Be Next
Beyond the leadership change, the possibility of another international partnership has attracted attention.
According to InsiderPH, information circulating within the conglomerate suggests that a large foreign medical group may soon partner with AC Health.
Such an arrangement could provide access to hospital management expertise, specialist networks, healthcare technology and international patient referral systems.
However, no definitive agreement with the unidentified medical group has been publicly established in the reporting reviewed.
The prospective company’s identity, potential investment amount, ownership arrangements and announcement timetable remain unknown.
Any suggestion that an acquisition or substantial equity investment has already been finalized would therefore be premature.
For now, the reported partnership remains a potential development rather than a confirmed transaction.
Singapore’s ABC Impact Already Holds a 16% Stake
The market speculation follows an earlier investment agreement involving Singapore-based ABC Impact, which acquired an approximately 16% minority stake in AC Health.
The investment was first announced in August 2025 and represented an important step in Ayala’s strategy to strengthen its healthcare capital base.
ABC Impact, backed by Temasek Trust, focuses on investments designed to deliver financial returns alongside measurable social and environmental outcomes.
In July 2026, the Presidential Communications Office reported that ABC Impact reaffirmed its support for AC Health’s expansion after representatives met Philippine President Ferdinand Marcos Jr. during his working visit to Singapore.
The partnership is supporting investments in hospitals, multi-specialty clinics and pharmacy operations.
Importantly, the ABC Impact investment is separate from the newly reported possibility of another foreign medical group joining AC Health.
The existing minority investment does not confirm that a second partnership has been agreed upon.
AC Health Targets 10 Hospitals, 300 Clinics and 1,150 Pharmacies
Ayala’s healthcare ambitions extend far beyond a single executive appointment.
According to the Presidential Communications Office, AC Health aims to expand its nationwide healthcare network to at least:
- 10 hospitals by 2027.
- 300 clinics by 2027.
- 1,150 pharmacies by 2027.
The proposed expansion is expected to support approximately 10,000 direct healthcare and retail jobs, depending on the final mix of facilities, acquisitions and investments.
These figures are expansion targets, not confirmed accomplishments.
The strategy reflects Ayala’s effort to create a more interconnected healthcare system that combines hospital treatment, outpatient consultations, medicines and other patient services.
For patients, such a model could improve coordination between different stages of healthcare, from initial consultations to specialist treatment and follow-up medication.
For the company, a wider network could create additional opportunities for operational efficiencies and cross-business collaboration.
Hospitals and Clinics Become Ayala’s Expansion Priority
The growing importance of AC Health is also reflected in Ayala Corporation’s corporate strategy.
During Ayala’s April 2026 annual stockholders’ meeting, company executives identified the expansion of hospitals and clinics as a major priority for the healthcare business.
The group pointed to opportunities similar to its acquisition of Cebu Velez General Hospital and its partnership with Far Eastern University–Dr. Nicanor Reyes Medical Foundation.
Ayala also highlighted continued development of its pharmaceutical operations, including Generika Drugstore, St. Joseph Drug and its Japanese-inspired wellness retail initiatives.
The strategy involves expanding healthcare facilities while developing a stronger distribution network for medicines and related products.
AC Health’s existing businesses provide a platform that a new foreign healthcare partner could potentially strengthen through specialist expertise, clinical systems or additional capital.
International Partnerships Strengthen Ayala’s Healthcare Network
AC Health has also been building partnerships with foreign healthcare organizations.
In October 2025, the company announced a collaboration with Taiwan’s Chang Gung Memorial Hospital, opening pathways for Filipino cancer patients to access specialized treatment, including proton therapy services.
In June 2026, AC Health announced a partnership with Japan’s Taisho Pharmaceuticals through AC Health Pharma to expand access to healthcare products.
These initiatives illustrate how Ayala is pursuing international collaboration across both medical services and pharmaceuticals.
The appointment of a former Bumrungrad executive adds another international dimension to that strategy.
Unlike a new acquisition, however, executive recruitment does not automatically mean the organizations previously associated with the executive are entering a corporate partnership.
There is no verified indication in the cited reporting that Bumrungrad International Hospital itself is the unidentified prospective investor or partner.
Why the Philippines’ Healthcare Market Matters
The Philippines offers substantial opportunities for healthcare infrastructure expansion, particularly in areas where access to hospitals, specialist physicians and affordable medicines remains uneven.
Private healthcare operators are seeking ways to improve service availability while responding to growing demand for diagnostics, specialty care and modern treatment facilities.
At the same time, expanding hospital networks requires significant investment in equipment, medical personnel, information systems and facility development.
A foreign healthcare partner with substantial operating experience could potentially help AC Health manage those challenges.
But the commercial benefits would depend on the nature of any partnership and whether it translates into improved patient outcomes, better access and financially sustainable operations.
The challenge for Ayala will be to balance opportunities in premium healthcare and medical tourism with its broader objective of delivering accessible healthcare to Filipinos.
The Bigger Question: Is Ayala Preparing for a Healthcare Transformation?
Tanthuwanit’s appointment comes at an important moment for AC Health.
The company already has an international minority investor, an expanding healthcare network and established partnerships with medical and pharmaceutical organizations across Asia.
A new foreign hospital operator could strengthen that foundation if a formal agreement eventually materializes.
But several questions remain unanswered.
Will AC Health announce a new strategic partnership? Could the arrangement involve an equity investment, operational collaboration or specialist hospital development? And will medical tourism become a major growth engine for the company’s next phase?
For now, the answers remain uncertain.
What is clear is that Ayala is pursuing a more ambitious healthcare strategy that extends beyond pharmacies and traditional hospital operations.
The arrival of a former Bumrungrad chief executive signals a stronger focus on international hospital management and medical tourism. But the bigger turning point may come if AC Health converts the reported foreign partnership discussions into a concrete agreement that expands its capabilities across the Philippine healthcare market.
For one of the Philippines’ largest conglomerates, the next major growth opportunity could lie not only in building more hospitals — but in creating a healthcare network capable of attracting international patients while delivering better services to millions of Filipinos.
